ViiV
Healthcare Launches New Patient Assistance Program and Participation
in Welvista Program for ADAP Waitlist Patients
ViiV
Healthcare is committed to putting patients at the center
of everything we do. We have met with many community leaders
across the country and the key theme consistently identified
was the need to help patients access medications. We have
listened and we have responded. In 2010, we extended our
patient savings card program and worked with the National
State and Territorial AIDS Directors and the ADAP Crisis
Task Force to address the unprecedented need for access
to antiretroviral medicines through AIDS Drug Assistance
Programs.
It gives me great pleasure to announce the implementation
of ViiV Healthcare's newest access initiatives, effective
January 1, 2011.
ViiV Healthcare Patient Assistance Program
The new program aims to do more to help increase access
for patients who cannot afford their medication or those
who were previously on medication who have now lost access
due to increasing ADAP income thresholds.
Patients are eligible to receive medications produced by
ViiV Healthcare up to one year and people who use Medicare
Part D are eligible to receive medications for the remainder
of the calendar year, once enrolled in the program.
Patients and patient advocates can visit (www.viivhealthcareforyou.com)
which provides details about the program including products
available, eligibility, and enrollment information.
Eligibility for ViiV Healthcare's new Patient Assistant
Program includes:
-
Patients without private or government supported prescription
coverage and who's household income level is no greater
than 500% of the Federal Poverty limit.
- Patients on ADAP waitlists who meet the Federal Poverty
Limit.
- People who use Medicare Part D who have spent $600 or
more in out-of-pocket and meet the Federal Poverty Limit.
M
Meachem. ViiV Healthcare Launches New Patient Assistance Program
and Participation in Welvista Program for ADAP Waitlist Patients.
Community announcement. January 3, 2010.
|
|
|